VR Logo

ContraFect Corporation (CFRX) download report


Healthcare | Biotechnology & Pharma Research

ContraFect Corporation (CFRX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States.

IPO Date: 29-Jul-2014

Chairman, CEO & Pres: Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.

Chief Financial Officer: Mr. Michael Messinger CPA, CPA

Listing: NASDAQ: CFRX

Country: United States

Headquarters: Yonkers, NY

Website: https://www.contrafect.com

Key Facts

Market cap: $120.75 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-35.18 Mln

Cash: $42.28 Mln

Total Debt: $3.17 Mln

Insider's Holding: 4.87%

Liquidity: Low

52 Week range: $2.11 - 4.76

Shares outstanding: 39,332,700

10 Years Aggregate:

  • CFO: $-249.24 Mln
  • EBITDA: $-277.76 Mln
  • Net Profit: $-241.15 Mln

Stock Performance

Time Period ContraFect (CFRX) S&P BSE Sensex* S&P Small-Cap 600*
YTD9.51-8.85-17.14
1 month-14.67-3.25-4.85
3 months-25.00-7.43-12.74
1 Year-37.120.33-16.37
3 Years-16.2310.287.97
5 Years-27.6211.396.33
10 Years--12.0810.54
As on 27-Jun-2022 *As on 28-Jun-2022
Year ContraFect (CFRX) S&P Small-Cap 600 S&P BSE Sensex
2021-47.9225.2721.99
2020-18.649.5715.75
2019-59.4320.8614.38
201851.14-9.705.87
2017-42.2911.7327.91
2016-63.1624.741.95
201535.71-3.36-5.03